The last Phase II announcement (released at 9:02 am on Monday, 18 December) was titled "P2 trial shows significant improvements in Phelan-McDermid". The key points were that "significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures" and "NNZ-2591 was safe and well tolerated, with no clinically significant changes in laboratory values or other safety parameters during treatment".
The share price closed up $5.06 (29.52%). It will be interesting to see how today's announcement compares in substance and effect on the share price. As others have noted, there is a case to be made that positive results today would be more valuable than the last announcement, since it would indicate that NNZ-2591 has potential across multiple indications.
Share Price, page-10264
-
- There are more pages in this discussion • 467 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.14 |
Change
0.155(0.78%) |
Mkt cap ! $2.570B | |||
| Open | High | Low | Value | Volume |
| $20.11 | $20.22 | $19.63 | $5.214M | 260.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 175 | $20.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.14 | 204 | 7 |
View Market Depth
| Last trade - 14.26pm 25/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |